MedTrace Logo

Experimental Expanded Access Treatment With Convalescent Plasma for the Treatment of Patients With COVID-19

NCT04445207 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2023-05-25

No results posted yet for this study

Summary

The purpose of this program is to see if giving convalescent plasma to individuals who test positive for COVID-19 may reduce their symptoms and help minimize complications from the illness.

Conditions

  • COVID
  • Sars-CoV2
  • Corona Virus Infection

Interventions

BIOLOGICAL

Convalescent Plasma

One to two 200 mL units of Convalescent plasma per infusion, up to 6 total units within a 3-week period.

Sponsors & Collaborators

  • Jonathan Gerber

    lead OTHER

Principal Investigators

  • Jonathan Gerber, MD · UMASS MEDICAL SCHOOL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04445207 on ClinicalTrials.gov